| Th 16. May 2019 |
|---|
Th 16:30-18:00
Bruselas E/F/G/H | Abstract Session 7: Pulmonary Hypertension and Heart Failure Working Group Symposium: Best Oral Abstracts Session
Chairs: Maurice Beghetti, Zdenka Reinhardt |
16:30-16:45 O7-1 
| Causes and outcomes of pulmonary hypertensions confirmed with right heart cath in infants younger than 6 months
Bonnet D., Bonino C., Szezepanski I., Malekzadeh-Milani S., Lévy M.
M3C-Necker Enfants malades, Université Paris Descartes, Paris, France |
16:45-17:00 O7-2
| A novel atrial flow egulator (AFR) device to control and assure blood flow after balloon atrioseptostomy (BAS) for severe, endstage pulmonary arterial Hypertension (PA)
Schulze-Neick I., Armbrust L., Jakob A., Herrmann M., Dalla-Pozza R., Haas N.A.
Pediatric Cardiology and Pediatric Intentive Care, Ludwig Maximilians University, Munich, Germany |
17:00-17:15 O7-3 
Best oral abstract PH | Early Pulmonary Hypertension in Extremely Premature born Infants: Results from a prospective cohort study (Neolifes-Heart)
Arjaans S.(1), Fries M.W.A.(1), Roofthooft M.T.R.(1), Kooi E.M.W.(2), Vrijlandt E.J.L.E.(3), Bos A.F.(2), Berger R.M.F.(1)
Department of Pediatric Cardiology, University of Groningen, University Medical Centre Groningen, the Netherlands (1);
Department of Neonatology, University of Groningen, University Medical Centre Groningen, the Netherlands (2);
Department of Pediatric Pulmonology, University of Groningen, University Medical Centre Groningen, the Netherlands (3) |
17:15-17:30 O7-4
| Von Willebrand factor reflects Fontan pathophysiology and strongly predicts the all-cause mortality
Ohuchi H., Negishi J., Iwasa T., Sakaguchi H., Shiraishi I., Kurosaki K.
National Cerebral and Cardiovascular Center, Suite, Japan |
17:30-17:45 O7-5
| Enalapril orodispersible minitablets (ODMTs) for children with heart failure – a successful EU-funded drug development program for children
Läer S.(1), Breitkreutz J.(2), Klingmann I.(3), Lagler F.(4), de Hoon J.(5), Dalinghaus M.(6), Bajcetic M.(7), de Wildt S.(6), Clarke A.K.(8), Breur H.(9), Male C.(10), Jovanovic I.(7), Djukic M.(7), Mir T.S.(11), Szatmári A.(12), Vukomanović V.(13), Ablonczy L.(13), Burckhardt B.B.(1), Cawello W.(1), Kleine K.(2), Obarcanin E.(1), Spatenkova L.(3), Swoboda V.(10), van der Meulen M.(6), Van Hecken A.(5), Wagner P.(1), Walsh J.(2) [for the LENA consortium and investigators]
Heinrich-Heine Universität Düsseldorf Düsseldorf Germany (1); Ethicare GmbH Haltern am See Germany (2); Pharmaplex BVBA Wezembeek-Oppem Belgium (3); Paracelsus Medizinische Privatuniversität Salzburg Austria (4); Katholieke Universiteit Leuven Belgium (5); Erasmus Universitair Medisch Centrum Rotterdam The Netherlands (6); Univerzitetska Dečja Klinika Belgrade Serbia (7); Children's Heart Federation on behalf of ECHDO London UK (8); Universitair Medisch Centrum Utrecht The Netherlands (9); Medizinische Universität Wien Austria (10); Universitätsklinikum Hamburg-Eppendorf Germany (11); Gottsegen György Hungarian Institute of Cardiology Budapest Ungarn (12); Institut za zdravstvenu zaštitu majke i deteta Srbije „dr Vukan Čupić“ Belgrade Serbia (13) |
17:45-18:00 O7-6
| Conversion to everolimus - a treatment option in pediatric heart transplant recipients: impact on CAV, renal function and cardiovascular risk factors
Grimm K.(1), Lehner A.(1), Fischer M.(1), Hakami L.(2), Rodriguez S.F.(1), Jakob A.(1), Haas N.(1), Ulrich S.(1)
Department of pediatric cardiology and intensive care medicine, Ludwig-Maximilians-University Munich, Munich, Germany (1); Department of pediatric cardiac surgery, Ludwig-Maximilians-University Munich, Munich, Germany (2) |
